Onemia®

Onemia® is Acasti’s first product to be marketed to healthcare practitioners and was introduced in the U.S. in 2011. As a medical food, Onemia® is only administered under the supervision of a physician and is intended for the specific dietary management of 404 Not Found illnesses associated with omega-3 phospholipid deficiency related to cardiometabolic disorders.

Onemia® consists of concentrated omega-3 phospholipids and antioxidants purified from krill oil, at a concentration which is considerably higher than that found in Neptune Krill Oil (NKO®).

Medical foods are a specific class of products under the U.S. Food and Drug Administration (FDA) and are defined by them as: “a food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on

The requested URL /c/counter.php was not found on this server.

recognized scientific principles, are established by medical evaluation.”

Acasti is positioning Onemia® to be the product of choice in a multimillion-dollar market targeting the clinical dietary management of cardiometabolic disorders. Nonclinical studies conducted by Acasti, supported by clinical testing conducted on Neptune Krill Oil (NKO®), have shown Onemia® to be safe and effective for the dietary management of omega-3 phospholipids deficiency and the related abnormal lipid profiles and cardiometabolic disorders.  Abnormal lipid profiles can lead to

Not Found

a number of conditions including hyperlipidemia (which generally manifests as high LDL (bad cholesterol) and high triglycerides), atherosclerosis (the build-up of plaque on the inside of blood vessels), diabetes, rheumatoid arthritis, and gastroenterology disorders.

Onemia® is now in the early stages of commercialization and has begun generating revenues for Acasti.  To date, Onemia® has been very well received by physicians and Acasti expects interest to build further as doctor’s confidence in its benefits increases.  

Initially, Onemia® is being distributed in the United States by Acasti to physicians, who then can either provide it to their patients directly or via a website by using a dedicated medical food access code. Acasti also makes Onemia® available via distributors and behind-the-counter in pharmacies. In 2012, Acasti entered into an agreement with a medical food distributor in the United States, which is distributing Onemia® through its network of dispensing physicians under its own brand name. Acasti intends to make Onemia® available via additional distributors and behind-the-counter in more pharmacies in the United States and to secure distribution partners to commercialize Onemia® outside of the United States.

Please visit Onemia's official web site : www.onemia.com